Almeida Molecular Imaging Foundation Corporation
- Assets
- $15.8k
- Revenue
- $0.0
- Investments
- $0.0
- Employees
- 0
- Location
- Scottsdale, AZ
- Founding
- 01/2014
- Data as of
- 12/2018
- EIN
- 46-4656040
Organization Overview
Almeida Molecular Imaging Foundation Corporation is located in Scottsdale, AZ. The organization was established in 2014. According to its NTEE Classification (P20) the organization is classified as: Human Service Organizations, under the broad grouping of Human Services and related organizations. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Almeida Molecular Imaging Foundation Corporation is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 12/2018, Almeida Molecular Imaging Foundation Corporation generated $10.8k in total revenue. This represents a relatively dramatic decline in revenue. Over the past 4 years, the organization has seen revenues fall by an average of (54.0%) each year. All expenses for the organization totaled $49.6k during the year ending 12/2018. You can explore the organizations financials more deeply in the financial statements section below.
Form
990EZ
Mission & Program ActivityExcerpts From the 990EZ Filing
TAX YEAR
2018
Describe the Organization's Mission:
Part 3 - Line 1
CANCER PUBLIC AWARENESS, EDUCATION, PATIENT EMPOWERMENT AND RESEARCH, WITH SPECIAL EMPHASIS ON PROSTATE CANCER.
Describe the Organization's Program Activity:
Part 3
CLINICAL TRIAL: PET IMAGING CHARACTERISTICS OF C11-ACETATE IN PATIENTS WITH PROSTATE CARCINOMA, DETECTION OF RECURRENT DISEASE WITH PSA RELAPSE. THE GOAL OF THIS STUDY IS IMPROVED IMAGING OF PROSTATE CANCER BY POSITRON EMISSION TOMOGRAPHY (PET) WITH USE OF THE RADIOPHARMACEUTICAL C-11 ACETATE, UTILIZING STATE-OF-THE-ART PET/CT CAMERA TECHNOLOGY AND PROCESSING ALGORITHMS. THE STUDY IS DESIGNED TO GENERATE DATA TO ADD TO THE UNDERSTANDING OF THE EFFECTIVENESS OF C-11 ACETATE, FOCUSING ON PATIENTS WITH RECURRENT OR PERSISTENT DISEASE AFTER PROSTATECTOMY OR RADIATION THERAPY.
CLINICAL TRIAL: C-11 SODIUM ACETATE PET/CT IMAGING FOR METASTATIC DISEASE IN INTERMEDIATE-TO-HIGH RISK PROSTATE ADENOCARCINOMA. THIS CLINICAL TRIAL IS STUDYING HOW THIS IMAGING TEST MAY HELP INFLUENCE THE CHOICE AND EXTENT OF INITIAL AND SUBSEQUENT TREATMENTS.
CLINICAL TRIAL: A PHASE III DOUBLE BLIND, PLACEBO CONTROLLED STUDY WITH A RANDOMIZATION ALLOCATION RATIO OF 1:1. THE STUDY PERIOD CONSISTS OF SCREENING/RANDOMIZATION, TREATMENT, ACTIVE FOLLOW-UP WITH CLINIC VISITS, ACTIVE FOLLOW-UP WITHOUT CLINIC VISITS, AND LONG-TERM FOLLOW-UP PHASES. IN THIS STUDY, SUBJECTS ARE RECEIVING STUDY TREATMENT.
Get More from Intellispect for FreeCreate a free account to get more data, nonprofit salaries, advanced search and more.
Board, Officers & Key Employees
| Name (title) | Role | Hours | Compensation |
|---|---|---|---|
Fabio Almeida President | 10 | $0 | |
Cynthia Almeida Vice President | 1 | $0 | |
Elisa Blackwell Secretary | 0 | $0 |
Financial Statements
| Statement of Revenue | |
|---|---|
| Total Revenue from Contributions, Gifts, Grants & Similar | $10,825 |
| Total Program Service Revenue | $0 |
| Membership dues | $0 |
| Investment income | $5 |
| Gain or Loss | $0 |
| Net Income from Gaming & Fundraising | $0 |
| Other Revenue | $0 |
| Total Revenue | $10,830 |
| Statement of Expenses | |
|---|---|
| Grants and similar amounts paid | $0 |
| Benefits paid to or for members | $0 |
| Salaries, other compensation, and employee benefits | $0 |
| Professional fees and other payments to independent contractors | $2,500 |
| Occupancy, rent, utilities, and maintenance | $0 |
| Printing, publications, postage, and shipping | $0 |
| Other expenses | $47,062 |
| Total expenses | $49,562 |
| Balance Sheet | |
|---|---|
| Cash, savings, and investments | $15,790 |
| Other assets | $0 |
| Total assets | $15,790 |
| Total liabilities | $0 |
| Net assets or fund balances | $15,790 |